Nolato

* Adj. EBITA SEK 262m (-2% vs. ABG, -3% vs. MFN cons) * Soft org. growth at 3% (ABG 6%), but Medical delivered 9% (ABG 7%) * We expect no material revisions to cons adj. EBITA Q3 outcome Sales came in at SEK 2,500m (-2% vs. ABG 2,543m, -1% vs. Modular...

* Q3e: sequential step-up in organic growth and margin * M&A the main driver behind our EBITA upgrades * Two new acquisitions end the three-year M&A hiatus Q3e: sequential step-up in organic growth and margin For Q3e, we expect Nolato to report net sales...

* Q2 below expectations, largely due to temporary effects * We cut our EBITA estimates by 3% for '26e, 1% for '27e-'28e * Organic growth to accelerate in H2e, and M&A potential on top Miss in Q2 driven mainly by temporary effects Nolato reported Q2 adj...

* Adj. EBITA SEK 253m (-7% vs. ABG, -3% vs. MFN cons) * We expect cons EBITA to come down by 2-3% * Share trading at 13-11x '26e-'27e EV/EBITA Q2 outcome Sales came in at SEK 2,454m (-1% vs. ABG 2,467m, 0% vs. Modular Finance cons 2,453m), up 2% y-o-...